Explore 3 Stock Ideas & Industry Insights Download Free Report
Vir Biotechnology
Vir Biotechnology (NASDAQ: VIR) is a clinical-stage biopharmaceutical company developing therapies for serious infectious diseases and cancer. Its pipeline includes elebsiran and tobevibart for chronic hepatitis delta, alongside PRO-XTEN-based dual-masked T-cell engagers targeting HER2, PSMA and EGFR in solid tumours. The company also maintains several preclinical infectious disease and oncology programmes.

Financial Performance for the second quarter ended June 30, 2026 (Q2FY26)
Enter your details below and our team will help you to decide if this product is best for you.
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
Past performance is not a reliable indicator of future performance.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…